Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E.
Rivera F, et al. Among authors: reboredo m.
Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.
Cancer Chemother Pharmacol. 2015.
PMID: 25491381
Clinical Trial.